1257293-88-1

Basic information

• Product Name: Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate
• Synonyms: Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate
• CAS NO: 1257293-88-1
• Molecular Formula: C12H22N2O3
• Molecular Weight: 242.31468
• Mol File: 1257293-88-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate(1257293-88-1)
• EPA Substance Registry System: Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate(1257293-88-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 1257293-88-1(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate is a chemical compound with a complex molecular structure. It is a derivative of piperazine, containing a tert-butyl group and a carboxylate functional group. The oxetan-3-yl moiety, a type of cyclic ether, is attached to the piperazine ring. Tert-Butyl 4-(oxetan-3-yl)piperazine-1-carboxylate is often used in organic synthesis and medicinal chemistry, with potential applications in drug discovery and development. Its unique structure and properties make it a valuable building block for creating new compounds with biological activity.

Upstream product

• 6704-31-0 oxetan-3-one 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1254115-23-5 1-(oxetan-3-yl)-piperazine 
• 1404373-75-6 1-(oxetan-3-yl)piperazine 2,2,2-trifluoroacetate 

Relevant articles and documents

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to ph